Checkmate 142 Nivolumab & amp; Ipilimumab 55Response Rate in MSI High
Cathy Eng, MD, FACP GASTROINTESTINAL MEDICAL ONCOLOGY - MD Anderson discusses the trial Checkmate 142 Nivolumab & Ipilimumab and how it has shown a 55% Response Rate in MSI High patients. Recorded...
Author: Gastrointestinal-Cancer-Meeting
Added: 01/25/2018
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts